Managing Pediatric Systemic Lupus Erythematosus in Thrombotic Thrombocytopenic Purpura
Researchers recommended performing lactate dehydrogenase level and blood smear testing in patients with renal and neurological symptoms.
Thrombotic Disorders
THROMBOTIC DISORDERS
FEATURE
LATEST ARTICLES
Risk Factors for Recurrent Venous Thromboembolism in Patients With Sickle Cell Disease
Patients with severe sickle cell disease were more than twice as likely to experience recurrent thromboembolism compared with patients with less severe disease.
Caplacizumab Associated With Improved Outcomes in Acquired Thrombotic Thrombocytopenic Purpura
Patients receiving caplacizumab experienced faster normalization of platelet count and fewer adverse events compared with patients on placebo.
Decreased Relapse, Mortality Rates With Rituximab in Acquired Thrombotic Thrombocytopenic Purpura
Researchers conducted a meta-analysis of 9 studies in patients receiving either rituximab or conventional treatment for TTP.
Second-Line Treatment Outcome Variability in Children With Immune Thrombocytopenia
Though all evaluated second-line treatments improved clinical outcomes, romiplostim was found to be the most effective at 6 months.
VTE-BLEED Risk Score Reliably Identifies Patients With PE at Risk for Major Bleeding
The VTE-BLEED risk score identified patients with pulmonary embolism at risk for in-hospital majorbleeding.
Outcomes With Eculizumab and Responses to Withdrawal for Atypical Hemolytic Uremic Syndrome
Among patients who underwent eculizumab withdrawal, 76.9% remained in remission during the course of the study.
Using Neural Networks to Assess Risk for Deep Vein Thrombosis
The neural network developed in this study yielded a false-negative rate of 0.22%.
Direct-Acting Oral Anticoagulant Treatment for Acute Venous Thromboembolism
Although clinical trials are ongoing, the safety profile and net clinical benefit of DOACs for acute venous thromboembolism treatment are unclear.
Optimal Approaches to Treating Venous Thromboembolism in Patients With Cancer
Recent studies suggest that direct-acting oral anticoagulants may be a viable treatment option for cancer patients with VTE, but more research is needed.
Long-Term Outcomes of Fostamatinib for Immune Thrombocytopenia
Researchers reviewed outcomes from several phase 3 trials assessing the feasibility of fostamatinib for immune thrombocytopenia.
Managing Neonatal Thrombocytopenia of Alloimmune Origin
A French working group developed a treatment algorithm for diagnosis and treatment of neonatal thrombocytopenia of suspected or confirmed alloimmune origin.
Apixaban May Reduce Risk for Venous Thromboembolism in Patients With Cancer
Significantly fewer patients receiving apixaban experienced thromboembolism and major bleeding compared with patients receiving placebo.
No Association Found Between Locations of Venous Thromboembolism and Occult Cancer
An analysis of 2300 patients found similar prevalence of abdominal, pelvic, and thoracic cancer in patients with deep vein thrombosis and pulmonary embolism.
Better Guidelines for Diagnosing Pulmonary Embolism During Pregnancy Needed
Current guidelines to diagnosis pulmonary embolism in pregnant patients offer conflicting recommendations.
Managing Venous Thromboembolism in Transgender Women Receiving Hormone Therapy
Transgender women receiving hormone replacement therapy may be at an increased risk for thromboembolism, though data and recommendations vary across studies.
Lack of Thromboprophylactic Benefit With Rivaroxaban in Ambulatory Patients With Cancer
Patients receiving rivaroxaban did not experience a statistically significant decrease in thrombotic events compared with patients receiving placebo.
Novel Risk Factors for Venous Thromboembolism in Pregnancy and Postpartum
Researchers assessed potential risk factors for venous thromboembolism during pregnancy and postpartum in more than 100,000 Japanese women.
Thromboprophylaxis May Not Benefit Patients With Advanced Cancer in Palliative Care
Thromboprophylactic treatment and serum albumin levels were not found to be associated with deep vein thrombosis incidence.
The Challenges of Treating Thromboinflammation
Because dysregulation of coagulation is a key feature of thromboinflammation, coagulation inhibitors may have therapeutic potential.
Case Study: Systemic Lupus Erythematosus With Lupus Nephritis and Thrombotic Microangiopathy
A 19-year-old woman presents with complaints of progressive shortness of breath, chest pain, and lower extremity edema over the past month.
Antithrombin Deficiency May Be Undertreated With Standard Heparin Therapy
Antifactor Xa activity after heparin spiking was lower in plasma samples from antithrombin-deficient patients compared with control samples.
Cablivi Approved for Acquired Thrombotic Thrombocytopenic Purpura
First FDA-approved therapy specifically indicated for the treatment of aTTP
Safety Comparison of Apixaban vs Rivaroxaban for Thromboembolism Prevention
Researchers conducted the first real world study to compare the safety and effectiveness of apixaban and rivaroxaban in patients with VTE.
A Serological Tool to Phenotypically Characterize Primary Antiphospholipid Syndrome
Researchers assessed the prevalence of various antiphosphatidylserine/prothrombin antibodies in patients with primary antiphospholipid syndrome.
Lower Platelet Transfusion Threshold in Neonates With Thrombocytopenia May Reduce Mortality
Researchers attempted to identify the appropriate platelet count transfusion threshold in preterm infants with severe thrombocytopenia.
Researchers Review Coagulation Risk Factors in Neonates and Children
The interactions between von Willebrand factors and its cleaving protease ADAMTS-13 recently emerged as risk factors for pediatric thromboembolism.
Statin Therapy May Reduce Thrombin Generation Potential in Patients With Thromboembolism
Statins may provide a therapeutic alternative to anticoagulant prophylaxis for venous thromboembolism.
Caplacizumab Cuts Time to Platelet Count Normalization in aTTP Patients
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
Upper Extremity Deep Vein Thrombosis May Be Linked to Post-Thrombotic Syndrome
Researchers conducted a systematic literature review to characterize the complications experienced by patients with upper extremity deep vein thrombosis.
Updated Clinical Practice Guidelines for Venous Thromboembolism: Pregnant and Pediatric Patients
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Updated Clinical Practice Guidelines for Venous Thromboembolism: Treatment Strategies
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Updated Clinical Practice Guidelines for Venous Thromboembolism: Diagnosis and Prophylaxis
In this 3-part series, Hematology Advisor spoke with experts about the revisions to the ASH clinical practice guidelines for venous thromboembolism.
Eltrombopag May Improve Quality of Life for Patients With Immune Thrombocytopenia
Changes in health-related quality of life in patients with persistent/chronic immune thrombocytopenia were evaluated using 4 different tools.
High Risk of Thrombosis in Myeloproliferative Neoplasms, Underlying Cause Still Unclear
The prevalence of thrombotic events in patients with myeloproliferative neoplasms can be as high as 39% in some cases.
Controversy Continues Over Relationship Between VTE and Testosterone Therapy
Current clinical data are insufficient to confirm or deny the potential association between risk for VTE and testosterone therapy.
Anticoagulant Therapies in Patients With Iliofemoral Deep Vein Thrombosis
No differences were observed in patency rates or incidence of post-thrombotic syndrome in patients treated with rivaroxaban or a vitamin K antagonist.
Rivaroxaban May Decrease Risk of Major Bleeding in Patients With Venous Thromboembolism
Compared with warfarin, rivaroxaban was found to reduce the risk of overall, gastrointestinal, and intracranial bleeding.
Risk Factors Affecting Venous Thromboembolism in Older White and Black Women With Breast Cancer
Women with breast cancer were found to experience increased risk of developing VTE.
FDA to Review Doptelet for Treatment of Chronic Immune Thrombocytopenia
Doptelet is a thrombopoietin receptor agonist (TPO-RA) that was approved in May 2018 to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a procedure.
Management of Venous Thrombosis in Unusual Sites
The incidence, pathophysiology, provoking factors, and recommended treatments for several types of unusual thrombosis were summarized in a review article.
Patients With Splanchnic Vein Thrombosis May Have Increased Risk of Bleeding and Arterial Cardiovascular Events
Researchers analyzed 1915 patients with splanchnic vein thrombosis for risk of bleeding and arterial cardiovascular events.
The Role of Viral Infections and Vaccines in the Pathogenesis of Antiphospholipid Syndrome
Recent evidence links specific bacterial, viral infections, and vaccination to the development of APS, but these associations are not clear-cut.
Eltrombopag Plus Azacitidine May Lead to Worse Survival in Patients With Myelodysplastic Syndrome
Up to 65% of patients with myelodysplastic syndrome experience comorbid thrombocytopenia.
Questions Remain Regarding Venous Thromboembolism Recurrence in Older Adults
Venous thromboembolism recurrence risk may not be any higher in older patients than in younger patients.
Long-Term Outcomes After Approval of Anagrelide for Essential Thrombocythemia
A retrospective review uncovered significantly decreased OS and MFFS in patients with essential thrombocythemia after the approval of anagrelide.
Eliminating H Pylori Infection May Benefit Adults With Immune Thrombocytopenic Purpura
The role of H Pylori in the development of immune thrombocytopenic purpura is still unclear.
Low Occurrence of Venous Thromboembolism With Weight-Adjusted Prophylaxis After Bariatric Surgery
Researchers performed a retrospective review of 1279 patients treated with a standardized, weight-adjusted tinzaparin regimen.
Product Availability Update for Gammaplex Immune Globulin
Gammaplex, an immune globulin, is indicated to treat chronic immune thrombocytopenic purpura (ITP) and primary humoral immunodeficiency.
BTK Inhibitor Designated Orphan Drug for Immune Thrombocytopenic Purpura
PRN1008 is an oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor; BTK is present in the signaling pathways of most types of white blood cells except for T cells and plasma cells.
Cryopreserved Platelets May Safely Reduce Bleeding in Patients With Thrombocytopenia
Bleeding scores improved in over half of the patients receiving cryopreserved platelets.
Want to read more?
Please login or register first to view this content.
Next post in Thrombotic Disorders
